Shilpa Medicare Limited · NSE:SHILPAMED
Shilpa Medicare — Q2 FY22 Earnings Presentation
24 slides from Shilpa Medicare's earnings presentation, Oct 29, 2021
Slide 1: Regulation 30 cover letter to stock exchanges
Shilpa Medicare Limited Corporate & Admin Office: “Shilpa House”, # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com CIN: L85110KA1987PLC008739 Dated: 29th October, 2021 To To Corporate Relati
Slide 2: Shilpa Medicare Limited Q2 FY22 Results Presentation
Shilpa Medicare Limited (SML) Q2 FY22 Results Presentation 1
Slide 3: Disclaimer
2 Disclaimer Certain statements in this document may be forward-looking statements. Such forward looking statements are subject to certain risks and uncertainties like regulatory changes, local political API Unit, Raichur or economic developments, and many other factors that could cause our actual r
Slide 4: Company Overview
Company Overview 3 Pursuing niche growth businesses like Biologics, Transdermal & Oral Dissolving Films Formulations Established presence in Active Pharmaceutical Ingredients (APIs) and Formulations for Affordable & Robust research domestic & international markets Effective orientation resulting in
Slide 5: Table of Contents
Table of Contents 4 Financial Performance........................................05 Discussion of Select Business Segments................... 09 Other Updates.................................................12 Way Forward……….........................................20
Slide 6: Financial Performance
Financial Performance | Innovating for ' affordable healthcare
Slide 7: Abridged P&L Statement - Consolidated
Abridged P&L Statement - Consolidated (Rs. In Lakhs) 6 Particulars Q2 FY22 Q2 FY21 Change (%) H1 FY22 H1 FY21 Change (%) Total Income (I+II) 29,655 28,814 3 53,590 51,648 4 I. Total Revenue from Operations (A+B+C+D) 29,527 27,894 6 53,263 50,180 6 •API (A) 19,055 16,508 15 32,170 32,556 (1) •Formula
Slide 8: Abridged P&L Statement - Standalone
Abridged P&L Statement - Standalone (Rs. In Lakhs) 7 Particulars Q2 FY22 Q2 FY21 Change (%) H1 FY22 H1 FY21 Change (%) Total Income (I+II) 29,498 27,020 9 54,512 48,947 11 I. Total Revenue from Operations (A+B+C+D) 28,587 26,268 9 52,620 47,931 10 •API (A) 19,055 16,508 15 32,170 31,216 3 •Formulati
Slide 9: Managing Director's Message
Managing Director’s Message 8 Commenting on Q2 FY’22 performance, Mr.Vishnukant Bhutada, Managing Director Shilpa Medicare Limited said “I am pleased to share we have improved our growth trajectory over the past quarters with a growth of 3%. Revenues for the quarter stood at Rs. 29,655 lakhs as agai
Slide 10: Discussion of Select Business Segments
Discussion of Select Business Segments 9
Slide 11: API - Highlights
API - Highlights 10 Segment wise sales (including service revenue) (Rs. In Lakhs) Q2 FY22 Q1 FY22 Q2 FY21 307 , 2% 405 , 3% 398 , 2% 2,972 , 15% 3,593 , 3,671 , 21% Oncology 27% Non-Oncology 4,730 , 11,352 , 9,531 , Crams 24% 59% 9,443 , 56% 3,383 , Others 71% 20% Rs. 19,453 Rs. 13,422 Rs. 16,913 •
Slide 12: Formulation - Highlights
Formulation - Highlights 11 Revenue Split (including service revenue) (Rs. In Lakhs) Q2 FY22 Q1 FY22 390 , 5% Q2 FY21 91 , 1% 351 , 4% 377 , 4% 385 , 4% 780 , 8% 3,220 , 5,419 , USA 36% 3,634 , 52% 40% EUROPE 4,522 , ROW 4,925 , 43% 4,396 , INDIA 55% 48% Rs. 8,912 Rs. 10,417 Rs. 9,161 • Actively wor
Slide 13: Other Updates
Other Updates 12
Slide 14: Contribution towards combating Covid-19 pandemic
Contribution towards combating to Covid-19 pandemic 13 Entered in an agreement with Cadila Healthcare Ltd (CHL) for production-supply of the ZyCov-D vaccine drug substance o The Company will manufacture the drug in its integrated Biologics R&D cum Manufacturing center at Dharwad, Karnataka through i
Slide 15: Contribution towards combating Covid-19 pandemic: Sputnik V update
Contribution towards combating to Covid-19 pandemic 14 Sputnik V vaccine update o Shilpa Biologicals Pvt Ltd, (SBPL) has entered in a 3-year definitive agreement with Dr. Reddy's Laboratories for the production-supply of SputnikV vaccine from its integrated Biologics R&D cum manufacturing center o T
Slide 16: Current Status on USFDA Warning Letter
Current Status on USFDA Warning Letter 15 USFDA updates on formulation facility o Completed gap assessment and ongoing remediation in place for the two major areas of concern cited by the USFDA ▪ Handling of complaints and ▪ Handling of laboratory investigations o A Master Compliance Action Plan wil
Slide 17: Patents Status as on September 30, 2021
Patents Status as on September30, 2021 16 Patents Filings Granted Pending - API 207 43 164 - Formulation * 182 28 154 - Films Topical & Transdermal 61 6 55 - Biologicals 12 4 8 - Others 22 5 17 TOTAL 484 86 398 * Formulation numbers includes the Patents of FTF Pharma Pvt Ltd Ahmedabad, a wholly owne
Slide 18: Formulation Product Pipeline as on September 30, 2021
Formulation Product Pipeline as on September 30, 2021 17 Regulatory Approved Filings Pending Submissions (Including Tentative) - US ANDA: SML 25 13 12 - US NDA: SML 03 01 02 - US ANDA: Customers 18 13 05 TOTAL (In US) 46 27 19 - EU Filing 25 18 07 - Row Filling 254 79 175 TOTAL (In EU & ROW) 279 97
Slide 19: Manufacturing Excellence
Manufacturing Excellence 18 Facility Location FacilityType Dharwad Biologicals Manufacturing plant & R & D Facility TDS & ODF Manufacturing Facility & Formulation Bengaluru Unit R&D Raichur Unit I API (Oncology – Non-Oncology) India India Raichur Unit II API (Oncology – Non-Oncology) and R & DAPI Ja
Slide 20: Ramping Up Capacities
Ramping Up Capacities Biologicals & Biosimilars ODF & Transdermal 19 API State-of-art mfg. facility to develop and manufacture novel 2 independent lines - single use lines (Expanded to 4000L tech-based products at Bengaluru facility for global market each) for production of MABS, vaccines and other
Slide 21: Way Forward
Way Forward 20
Slide 22: Way Forward
Way Forward… 21 o Separate business under Shilpa Lifesciences Pvt. Ltd to provide focused approach resulting in better operating efficiency o Greater impetus to specialty areas of CDMO, Peptides & Polymers API o One Production block likely to get commissioned in next quarter and also planning to inc
Slide 23: About Shilpa Medicare Ltd.
About Shilpa Medicare Ltd. 22 Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1989 at Raichur, Karnataka- India. Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of affordable API and Formulation globally in different regulated marke
Slide 24: Thank You
23 Thank You